N/A
Completed N=211
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
Source: ClinicalTrials.gov NCT00904371 ↗Enrolled (actual)
211
Serious AEs
1.0%
Results posted
Aug 2012
Primary outcomePrimary: Change From Baseline in Systolic Blood Pressure (SBP) — -22.6 mm Hg
Summary
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Systolic Blood Pressure (SBP) |
-22.6 | — |
| PRIMARY Change From Baseline in Diastolic Blood Pressure (DBP) |
-10.1 | — |
| PRIMARY Change From Baseline in SCORE (10 Year Risk for Fatal Cardiovascular Event) |
-3.9 | — |
| PRIMARY Change From Baseline in Framingham CVD Risk Assessment Score |
-7.6 | — |
| PRIMARY Change From Baseline in Framingham Stroke Risk Assessment Score |
-3.6 | — |
| PRIMARY Change From Baseline in Risk Assessment According to ESH/ESC Guidelines |
18; 7; -13; -12 | — |
| SECONDARY Pecentage of Patients That Achieved Target Blood Pressure (BP) Values According to ESH/ESC |
32.8; 67.2 | — |
| SECONDARY Additional Antihypertensive Treatment Pattern at Visit 3 (End of Study) |
19; 11.2; 32.2; 36.1; 9.3 | — |
| SECONDARY Change in Heart Rate From Baseline to Study End |
-3.2 | — |
| SECONDARY Number of Patients With Adverse Events (AE) |
4 | — |
| SECONDARY Number of Participants Not Completing Study |
2; 4; 2; 1 | — |
Eligibility Criteria
Inclusion criteria
- diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for diabetic patients)
- at least an additional cardiovascular risk factor
Exclusion criteria
- hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market
- pregnancy and lactation
- diseases involving biliary obstruction
- severe liver impairment
Data sourced from ClinicalTrials.gov (NCT00904371). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.